Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23429008)

1.

NHE-1: still a viable therapeutic target.

Karmazyn M.

J Mol Cell Cardiol. 2013 Aug;61:77-82. doi: 10.1016/j.yjmcc.2013.02.006. Epub 2013 Feb 18. Review.

PMID:
23429008
2.

[[Meldonium in treatment of patients with myocardial infarction].

Nechaeva GI, Potashov DA, Zheltikova EN.

Kardiologiia. 2014;54(9):93-6. Review. Russian.

PMID:
25702409
3.

Response to the paper by Ünlü et al. entitled 'The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts'.

Li J, Song SJ.

Cardiology. 2015;130(1):54. doi: 10.1159/000369297. Epub 2014 Dec 13. No abstract available.

PMID:
25531774
4.

ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies.

Lecour S, Bøtker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ.

Cardiovasc Res. 2014 Dec 1;104(3):399-411. doi: 10.1093/cvr/cvu225. Epub 2014 Oct 24.

5.

Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation.

Kilić A, Huang CX, Rajapurohitam V, Madwed JB, Karmazyn M.

J Pharmacol Exp Ther. 2014 Dec;351(3):492-9. doi: 10.1124/jpet.114.217091. Epub 2014 Sep 12.

PMID:
25216745
6.

Epoxyeicosatrienoic acids and cardioprotection: the road to translation.

Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM.

J Mol Cell Cardiol. 2014 Sep;74:199-208. doi: 10.1016/j.yjmcc.2014.05.016. Epub 2014 Jun 2. Review.

PMID:
24893205
7.

The cardioprotective effects of novel Na+/H+ exchanger inhibitor TY-51924 on ischemia/reperfusion injury.

Sasamori J, Hasegawa T, Takaya A, Watanabe Y, Tanaka M, Ogino Y, Chiba T, Aihara K.

J Cardiovasc Pharmacol. 2014 Apr;63(4):351-9. doi: 10.1097/FJC.0000000000000055.

PMID:
24336011
8.

Sodium-hydrogen exchangers (NHE) in human cardiovascular diseases: interfering strategies and their therapeutic applications.

Madonna R, De Caterina R.

Vascul Pharmacol. 2013 Nov-Dec;59(5-6):127-30. doi: 10.1016/j.vph.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24140414
9.

Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity disorder? An in silico approach.

Faraone SV, Zhang-James Y.

Am J Med Genet B Neuropsychiatr Genet. 2013 Oct;162B(7):711-7. doi: 10.1002/ajmg.b.32155.

PMID:
24132903
10.
11.

[Structure and physiological role of NHE1 and pharmacological regulation of its activity].

Spasov AA, Gurova NA, Kharitonova MV.

Eksp Klin Farmakol. 2013;76(1):43-8. Review. Russian.

PMID:
23461016
12.

Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

Hausenloy DJ, Erik Bøtker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M.

Cardiovasc Res. 2013 Apr 1;98(1):7-27. doi: 10.1093/cvr/cvt004. Epub 2013 Jan 19. Review.

13.

Inhibition of Na⁺-H⁺ exchange as a mechanism of rapid cardioprotection by resveratrol.

Thuc LC, Teshima Y, Takahashi N, Nishio S, Fukui A, Kume O, Saito S, Nakagawa M, Saikawa T.

Br J Pharmacol. 2012 Jul;166(6):1745-55. doi: 10.1111/j.1476-5381.2012.01877.x.

14.

NHE inhibition does not improve Na(+) or Ca(2+) overload during reperfusion: using modeling to illuminate the mechanisms underlying a therapeutic failure.

Roberts BN, Christini DJ.

PLoS Comput Biol. 2011 Oct;7(10):e1002241. doi: 10.1371/journal.pcbi.1002241. Epub 2011 Oct 20.

15.

Myocardial protection in heart surgery.

Mentzer RM Jr.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):290-7. doi: 10.1177/1074248411410318. Review.

PMID:
21821531
16.

State of the science of cardioprotection: Challenges and opportunities--proceedings of the 2010 NHLBI Workshop on Cardioprotection.

Kloner RA, Schwartz Longacre L.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):223-32. doi: 10.1177/1074248411402501.

PMID:
21821520
17.

Disruption of chronic cariporide treatment abrogates myocardial ion homeostasis during acute ischemia reperfusion.

Bourahla V, Dubouchaud H, Mourmoura E, Vitiello D, Faure P, Migné C, Pujos-Guillot E, Richardson M, Demaison L.

J Cardiovasc Pharmacol. 2011 Sep;58(3):284-94. doi: 10.1097/FJC.0b013e318223ebb2.

PMID:
21697734
18.

Mitochondrial KATP channels participate in the limitation of infarct size by cariporide.

Nuñez IP, Fantinelli J, Arbeláez LF, Mosca SM.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):563-71. doi: 10.1007/s00210-011-0632-z. Epub 2011 Apr 12.

PMID:
21484437
19.

Resuscitation after prolonged cardiac arrest: effects of cardiopulmonary bypass and sodium-hydrogen exchange inhibition on myocardial and neurological recovery.

Liakopoulos OJ, Hristov N, Buckberg GD, Triana J, Trummer G, Allen BS.

Eur J Cardiothorac Surg. 2011 Oct;40(4):978-84. doi: 10.1016/j.ejcts.2011.02.002. Epub 2011 Mar 11.

20.

AVE4454B--a novel sodium-hydrogen exchanger isoform-1 inhibitor--compared less effective than cariporide for resuscitation from cardiac arrest.

Radhakrishnan J, Kolarova JD, Ayoub IM, Gazmuri RJ.

Transl Res. 2011 Feb;157(2):71-80. doi: 10.1016/j.trsl.2010.11.004. Epub 2010 Dec 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk